Commitments and Contingencies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 9 - Commitments and Contingencies |
a) Capital Lease Obligations
In 2015, the Company entered into an equipment capital lease to purchase three Tecan machines (automated liquid handling robots) for 550,454 Euros. As of March 31, 2018, the balance payable was $220,707. In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (ING) to purchase a property located in Belgium for 1.12 million Euros. As of March 31, 2018, the balance payable was $786,928. The following is a schedule showing the future minimum lease payments under capital leases by years and the present value of the minimum payments as of March 31, 2018.
b) Operating Lease Obligations
The Company also leases premises and facilities under operating leases with terms ranging from 12 months to 60 months. As of March 31, 2018, the annual non-cancelable operating lease payments on these leases are as follows:
c) Grants Repayable
In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for 1.05 million Euros. Per the terms of the agreement, 314,406 Euros of the grant is to be repaid. As of March 31, 2018, the balance repayable was $237,173 and the annual payments remaining were as follows:
d) Long-Term Debt
In 2016, the Company entered into a 7-year loan agreement with Namur Invest for 440,000 Euros with a fixed interest rate of 4.85%. As of March 31, 2018, the principal balance payable was $494,267. In 2016, the Company entered into a 15-year loan agreement with ING for 270,000 Euros with a fixed interest rate of 2.62%. As of March 31, 2018, the principal balance payable was $310,307. In 2017, the Company entered into a 4-year loan agreement with Namur Invest for 350,000 Euros with a fixed interest rate of 4.00%. As of March 31, 2018, the principal balance payable was $412,228. In 2017, the Company entered into an 11-month loan agreement with ING for 200,000 Euros with a rolling interest rate of the Euribor rate + 2.00%. As of March 31, 2018, the principal balance payable was $246,534. In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to 1 million Euros with a fixed interest rate of 4.50%. As of March 31, 2018, 250,000 Euros has been drawn down under this agreement and the principal balance payable was $308,167. As of March 31, 2018, the total balance for long-term debt payable was $1,771,503 and the annual payments remaining were as follows:
e) Collaborative Agreement Obligations
In 2015, the Company entered into a research sponsorship agreement with DKFZ, in Germany for a 3-year period for 338,984 Euros. As of March 31, 2018, $92,450 is still to be paid by the Company under this agreement. In 2016, the Company entered into a research co-operation agreement with DKFZ, in Germany for a 5-year period for 400,000 Euros. As of March 31, 2018, $246,534 is still to be paid by the Company under this agreement. In 2016, the Company entered into a collaborative research agreement with Munich University, in Germany for a 3-year period for 360,000 Euros. As of March 31, 2018, $234,207 is still to be paid by the Company under this agreement. In 2016, the Company entered into a phase one clinical research agreement with Hvidovre Hospital, University of Copenhagen in Denmark for a 2-year period for DKK 15 million Danish Kroner. As of March 31, 2018, $708,639 is still to be paid by the Company under this agreement. In 2017, the Company entered into a research collaboration agreement with National University of Singapore for a 2-year period for $48,000. As of March 31, 2018, $9,600 is still to be paid by the Company under this agreement. In 2017, the Company entered into a clinical study research agreement with the Regents of the University of Michigan (the University of Michigan) for a 3-year period for up to $3 million. As of March 31, 2018, up to $2.5 million is still to be paid by the Company under this agreement. As of March 31, 2018, the total amount to be paid for future research and collaboration commitments was $3,791,430 and the annual payments remaining were as follows:
f) Legal Proceedings
There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. |